Finance entity
Grail is most often covered alongside Bob Ragusa, which appears in 1 of these 2 stories. The 31-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Grail is most often covered alongside Bob Ragusa, which appears in 1 of these 2 stories. The 31-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 6, the average consequence score sits below the same-window beat average of 6.3. We currently track 2 Finance stories that mention Grail, published between February 20, 2026 and March 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 2471 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grail. Shared-story counts are live from our verified record — not editorial picks.
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Candel Public Offering
Candel Therapeutics prices $100M public offering at $5.45 per share.
Trial Data Release
Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
GDP Release
U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
Grail Earnings
Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.
Source: Benzinga · benzinga.com
Grail is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
